Santhera ends development of idebenoneSwiss Santhera Pharmaceuticals has discontinued Phase III development of its DMD drug and will restructure its pipeline. more ➔
Nobel Prize in Physiology for HCV pioneersThe Nobel Prize in Physiology or Medicine goes to Harvey J. Alter, Michael Houghton and Charles M. Ric more ➔
Swiss Sophia Genetics to expand globallySwiss Sophia Genetics has raised $110m, to expand marketing of its AI-driven cancer and genetic disease decision support platform globally. more ➔
EIB and EC launch circular bioeconomy fundThe European Commission (EC) and the European Investment Bank (EIB) have launched a circular bioeconomy fund with a target size of €250m. more ➔ · more ➔
Dewpoint Therapeutics raise $77m in Series...A $77 Series B financing allows Dewpoint Therapeutics Inc to select a lead programme from its new drug class of molecular condensates and push proof-of-concept studies. more ➔
Kurma Partners close diagnostics fund at ...The only investment fund dedicated to breakthrough diagnostics, Kurma Diagnostics 2, had its first closing at €50m. more ➔
Danish Galecto Inc. secures US$64m equity...Danish fibrosis and cancer specialist Galecto Inc. has raised US$64m in a Series B round led by Soleus Capital. more ➔
MosaMeat NV bags US$55m financingMaastricht-based cultured meat producer Mosa Meat NV has raised $55m in a Series B financing, bringing its funding to $63.8m. more ➔
Pureos Bioventures closes US$170m fundNewly formed venture capitalist Pureos Bioventures has set up a US$170m fund dedicated to Swiss and European drug developers. more ➔
Biotechs request money for COVID therapeut...German biotech companies and their industry association BIO Deutschland have called for appropriate investments into clinical COVID-19 therapies. more ➔
